Sarepta Therapeutics Stock Plummets 42.32% in Two Days, Trading Volume Ranks 96th

On May 7, 2025, Sarepta Therapeutics (SRPT) experienced a significant decline, with its stock price dropping by 21.45% over the course of two consecutive days, resulting in a total decrease of 42.32%. The company's trading volume reached $783 million, placing it at the 96th position in terms of daily trading volume.

Sarepta Therapeutics, Inc. has faced a setback with its gene therapy SRP-9003 for the LGMD 2E/R4 subtype, which is progressing with a potential Biologics License Application (BLA) submission in the second half of 2025. This development could potentially boost shareholder value. However, the company's stock rating has been changed from "Strong Buy" to "Hold" due to underperformance and safety concerns with ELEVIDYS, as well as increased expenses. Despite these challenges, Sarepta maintains strong long-term fundamentals.

In the first quarter of 2025, Sarepta reported a loss of $3.42 per share, missing the analyst consensus estimate of $0.95 per share. This disappointing financial performance has led analysts to slash their forecasts for the company. Additionally, Sarepta has temporarily halted three trials testing its gene therapy Elevidys due to safety concerns, further impacting investor sentiment.

Sarepta's recent corporate developments include updates on its clinical programs focused on limb-girdle muscular dystrophy, as well as the announcement of inducement grants under Nasdaq Listing Rule 5635(c)(4). The company continues to face legal investigations related to potential claims on behalf of its investors, which adds to the uncertainty surrounding its stock performance.